These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 14746860

  • 21. Treatment outcomes and prognostic factors in children with hepatoblastoma using a risk-stratified approach.
    Srinivasan S, Prasad M, Parambil BC, Shrimal A, Gollamudi VRM, Subramani V, Ramadwar M, Khanna N, Baheti AD, Gala K, Patil V, Laskar S, Qureshi S, Chinnaswamy G.
    Pediatr Blood Cancer; 2023 Jul; 70(7):e30302. PubMed ID: 37046413
    [Abstract] [Full Text] [Related]

  • 22. Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737.
    Lieber J, Dewerth A, Wenz J, Kirchner B, Eicher C, Warmann SW, Fuchs J, Armeanu-Ebinger S.
    Oncol Rep; 2013 Feb; 29(2):646-52. PubMed ID: 23229825
    [Abstract] [Full Text] [Related]

  • 23. Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies.
    Illiano M, Colinard M, Taque S, Mallon B, Larue C, Laithier V, Vérité-Goulard C, Sudour-Bonnange H, Faure-Conter C, Coze C, Aerts I, De Maricourt CD, Paillard C, Branchereau S, Brugières L, Fresneau B.
    Hepatol Int; 2022 Feb; 16(1):125-134. PubMed ID: 34506008
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Resectability and tumor response after preoperative chemotherapy in hepatoblastoma treated by the Japanese Study Group for Pediatric Liver Tumor (JPLT)-2 protocol.
    Hiyama E, Hishiki T, Watanabe K, Ida K, Yano M, Oue T, Iehara T, Hoshino K, Koh K, Tanaka Y, Kurihara S, Ueda Y, Onitake Y.
    J Pediatr Surg; 2016 Dec; 51(12):2053-2057. PubMed ID: 27712887
    [Abstract] [Full Text] [Related]

  • 27. Carboplatin and doxorubicin (CARDOX) for nonmetastatic hepatoblastoma: a discouraging pilot study.
    Dall'Igna P, Cecchetto G, Dominici C, Donfrancesco A, Carli M, Indolfi P, Guglielmi M, Perilongo G.
    Med Pediatr Oncol; 2001 Feb; 36(2):332-4. PubMed ID: 11452948
    [No Abstract] [Full Text] [Related]

  • 28. Tumor rupture in hepatoblastoma: A high risk factor?
    Pondrom M, Pariente D, Mallon B, Taque S, Branchereau S, Chardot C, Laithier V, Tabone MD, Lejeune J, Faure-Conter C, Saumet L, Vérité C, Aerts I, Brugières L, Fresneau B.
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28549. PubMed ID: 32618436
    [Abstract] [Full Text] [Related]

  • 29. Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group.
    O'Neill AF, Towbin AJ, Krailo MD, Xia C, Gao Y, McCarville MB, Meyers RL, McGahren ED, Tiao GM, Dunn SP, Langham MR, Weldon CB, Finegold MJ, Ranganathan S, Furman WL, Malogolowkin M, Rodriguez-Galindo C, Katzenstein HM.
    J Clin Oncol; 2017 Oct 20; 35(30):3465-3473. PubMed ID: 28892430
    [Abstract] [Full Text] [Related]

  • 30. Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors.
    Casanova M, Massimino M, Ferrari A, Spreafico F, Piva L, Coppa J, Luksch R, Cefalo G, Terenziani M, Polastri D, Bellani FF, Mazzaferro V.
    Pediatr Hematol Oncol; 2005 Oct 20; 22(3):189-98. PubMed ID: 16020101
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Redefining the role of doxorubicin for the treatment of children with hepatoblastoma.
    Malogolowkin MH, Katzenstein HM, Krailo M, Chen Z, Quinn JJ, Reynolds M, Ortega JA.
    J Clin Oncol; 2008 May 10; 26(14):2379-83. PubMed ID: 18467729
    [Abstract] [Full Text] [Related]

  • 33. Single-agent cisplatin treatment of children with high-risk hepatoblastoma.
    Zhang YT, Feng LH, Zhong XD, Wang LZ, Chang J.
    J Pediatr Hematol Oncol; 2014 May 10; 36(4):271-5. PubMed ID: 24309602
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A trend of improved survival of childhood hepatoblastoma treated with cisplatin and doxorubicin in Taiwanese children.
    Chiu SN, Ni YH, Lu MY, Lin DT, Lin KH, Lai HS, Chang MH.
    Pediatr Surg Int; 2003 Oct 10; 19(8):593-7. PubMed ID: 14556026
    [Abstract] [Full Text] [Related]

  • 36. Treatment-related acute myelomonocytic leukemia with t(11;19) in a child following chemotherapy for hepatoblastoma.
    Koga Y, Matsuzaki A, Suminoe A, Washitoh N, Hara T, Hara T, Tajiri T, Taguchi T.
    Pediatr Blood Cancer; 2008 Apr 10; 50(4):943-4. PubMed ID: 17973320
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Improved long-term survival with preoperative chemotherapy for hepatoblastoma.
    Ehrlich PF, Greenberg ML, Filler RM.
    J Pediatr Surg; 1997 Jul 10; 32(7):999-1002; discussion 1002-3. PubMed ID: 9247221
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
    Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA.
    N Engl J Med; 2018 Jun 21; 378(25):2376-2385. PubMed ID: 29924955
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.